Shih-Hao Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shih-Hao Su has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Yu Feng
Department of Medical Education, National Taiwan University Hospital, Taipei 100225, Taiwan
1 shared publication - Chih-Feng Lin
Department of Otolaryngology- Head and Neck Surgery, National Taiwan University Hospital, Taipei, Taiwan
1 shared publication - Ting-Hua Yang
Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan
1 shared publication - Yi-Shyue Chen
Department of Otolaryngology- Head and Neck Surgery, National Taiwan University Hospital, Taipei, Taiwan
1 shared publication - Yu-Han Wang
Department of Medical Education, National Taiwan University Hospital, Taipei 100225, Taiwan
1 shared publication
Latest Publications
- Open Access
Recurrence of Chronic Rhinosinusitis with Nasal Polyps After Surgery: Risk Factors, Predictive Models, and Treatment Approaches with a Focus on Western and Asian Differences
Background and Objectives: Chronic rhinosinusitis (CRS) frequently recurs following endoscopic sinus surgery (ESS), yet reported recurrence rates, risk factors, and treatment responses differ significantly across regions. This review aims to synthesize current evidence on recurrence patterns, predictive models, and treatment strategies, with a focus on comparing Asian and Western populations. Materials and Methods: A structured narrative review was conducted by searching PubMed, Embase, and Cochrane Library from January 2010 to June 2025. A total of 116 studies were included based on predefined criteria regarding recurrence definitions, risk factors, prediction models, and postoperative management. Results: Recurrence rates ranged from 12% to 76.6%, with wide variability attributed to differences in follow-up duration and recurrence definitions. Key risk factors included tissue eosinophilia, comorbid asthma, and type 2 inflammation. Asian predictive models emphasized inflammatory biomarkers such as tissue and blood eosinophils, whereas Western models incorporated imaging, prior surgical history, and symptom burden. While biologics are widely used in the West, their adoption remains limited in Asia, where endotype-driven corticosteroid strategies are predominant. Conclusions: CRS recurrence after ESS is influenced by inflammatory endotypes, comorbidities, and regional treatment paradigms. Cross-regional differences in immune profiles and healthcare access necessitate the development of standardized definitions and validated, endotype-driven prediction tools. Tailored treatment strategies, especially for non-type 2 CRS, are essential to achieving equitable and effective care globally.
Open AccessRecurrence of Chronic Rhinosinusitis with Nasal Polyps After Surgery: Risk Factors, Predictive Models, and Treatment Approaches with a Focus on Western and Asian Differences
Background and Objectives: Chronic rhinosinusitis (CRS) frequently recurs following endoscopic sinus surgery (ESS), yet reported recurrence rates, risk factors, and treatment responses differ significantly across regions. This review aims to synthesize current evidence on recurrence patterns, predictive models, and treatment strategies, with a focus on comparing Asian and Western populations. Materials and Methods: A structured narrative review was conducted by searching PubMed, Embase, and Cochrane Library from January 2010 to June 2025. A total of 116 studies were included based on predefined criteria regarding recurrence definitions, risk factors, prediction models, and postoperative management. Results: Recurrence rates ranged from 12% to 76.6%, with wide variability attributed to differences in follow-up duration and recurrence definitions. Key risk factors included tissue eosinophilia, comorbid asthma, and type 2 inflammation. Asian predictive models emphasized inflammatory biomarkers such as tissue and blood eosinophils, whereas Western models incorporated imaging, prior surgical history, and symptom burden. While biologics are widely used in the West, their adoption remains limited in Asia, where endotype-driven corticosteroid strategies are predominant. Conclusions: CRS recurrence after ESS is influenced by inflammatory endotypes, comorbidities, and regional treatment paradigms. Cross-regional differences in immune profiles and healthcare access necessitate the development of standardized definitions and validated, endotype-driven prediction tools. Tailored treatment strategies, especially for non-type 2 CRS, are essential to achieving equitable and effective care globally.